Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET

Company Participants

Chris Taylor - Vice President, Investor Relations and Corporate Communications
Brian Goff - Chief Executive Officer
Sarah Gheuens - Chief Medical Officer and Head, R&D
Tsveta Milanova - Chief Commercial Officer
Cecilia Jones - Chief Financial Officer

Conference Call Participants

Greg Harrison - Scotiabank
Alex Nackenoff - Raymond James
Greg Renza - RBC Capital Markets
Eric Schmidt - Cantor Fitzgerald
Chris Raymond - Piper Sandler
Tessa Romero - JPMorgan
Divya Rao - TD Cowen
Alec Stranahan - Bank of America
Lydia Erdman - Goldman Sachs
Andrew Berens - Leerink Partners

Operator

Good morning, and welcome to Agios' Third Quarter 2024 Conference Call. [Operator Instructions] Please be advised that today's call is being recorded at Agios' request.

I would now like to turn the call over to Chris Taylor, Vice President, Investor Relations and Corporate Communications for Agios.

Chris Taylor

Thank you, operator. Good morning, everyone, and welcome to Agios' conference call and webcast to discuss our third quarter 2024 financial results and recent business highlights. You can access the slides for today's call by going to the Investors section of our website, agios.com.

On today's call, I'm joined by our Chief Executive Officer, Brian Goff; Dr. Sarah Gheuens, Chief Medical Officer and Head of R&D; Tsveta Milanova, Chief Commercial Officer; and Cecilia Jones, Chief Financial Officer.

Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those we set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC.

And with that, turn the call over to Brian.

Brian Goff

Thanks, Chris. Good morning, everyone, and thank you for joining us.

Our mission at Agios is to develop and deliver transformative medicines that elevate and extend the lives of patients living with rare diseases. We are especially focused on rare diseases that result in the dysfunction and destruction of red blood cells, including pyruvate kinase deficiency or PKD, thalassemia, sickle cell disease and lower risk myelodysplastic syndrome or MDS. As red blood cells comprise over 80% of all cells in the human body, optimizing red cell health represents an important path to improved individual health.